Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Mechanisms, Clinical Efficacy in Weight Management, and Clinical Implications
Executive Summary GLP-1 receptor agonists (GLP-1 RAs) represent a transformative class of incretin-based therapeutics originally developed for type 2 diabetes (T2D), now proven to yield robust, clinically meaningful weight loss. Mechanisms extend beyond glycemic control to include central appetite suppression, delayed gastric emptying, and modulation of energy expenditure. High-evidence data—from phase 3 randomized controlled trials…